Physician profile
Kyle Sullivan
NPI 1902444342
$4,576.34
in general payments reported to CMS, 2019-2025
20 companies · $1,733 in 2025
The $1,733 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $278 · 2022: $397 · 2023: $511 · 2024: $1,657 · 2025: $1,733.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,149 · Travel and Lodging: $1,752.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,148.70 |
| Travel and Lodging | $1,752.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,929.92 | 2021-2025 | Minimed 780g, Minimed 770g |
| Arthrex, INC. | $1,069.90 | 2025 | |
| Insulet Corporation | $278.50 | 2023-2025 | Omnipod |
| Abbott Laboratories | $223.66 | 2023-2024 | Freestyle Libre 3 |
| Lilly USA, LLC | $152.53 | 2022-2025 | Mounjaro, Zepbound |
| Lightbody Medical Technologies INC | $149.99 | 2025 | |
| Amgen INC. | $132.86 | 2021-2025 | Evenity, Prolia, Prolia |
| Dexcom, INC. | $119.74 | 2021-2025 | Dexcom G6 Transmitter |
| Beta Bionics, INC. | $104.98 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Tandem Diabetes Care, INC. | $100.42 | 2021-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbvie INC. | $61.45 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $51.68 | 2025 | |
| Tolmar, INC. | $50.05 | 2023-2025 | Jatenzo |
| Astellas Pharma US INC | $30.40 | 2025 | Veozah |
| Esperion Therapeutics, INC. | $24.68 | 2025 | Nexletol |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $22.14 | 2023 | Gvoke Hypopen |
| Sequel Med Tech, LLC | $22.00 | 2025 | Twiist |
| Novartis Pharmaceuticals Corporation | $21.09 | 2025 | |
| Novo Nordisk INC | $18.06 | 2024 | Ozempic |
| Vistapharm, INC. | $12.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Sullivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.